1. Home
  2. IMXI vs CELC Comparison

IMXI vs CELC Comparison

Compare IMXI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$12.10

Market Cap

469.3M

Sector

Technology

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$81.57

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
CELC
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.3M
4.2B
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
IMXI
CELC
Price
$12.10
$81.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$15.00
$112.56
AVG Volume (30 Days)
357.6K
755.4K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$319,601,000.00
N/A
Revenue This Year
$0.83
N/A
Revenue Next Year
$1.49
$720.19
P/E Ratio
$84.13
N/A
Revenue Growth
16.68
N/A
52 Week Low
$11.15
$44.42
52 Week High
$15.95
$151.02

Technical Indicators

Market Signals
Indicator
IMXI
CELC
Relative Strength Index (RSI) 30.23 37.66
Support Level $11.21 $78.60
Resistance Level $14.77 $96.39
Average True Range (ATR) 0.32 3.55
MACD -0.24 -0.94
Stochastic Oscillator 7.33 6.33

Price Performance

Historical Comparison
IMXI
CELC

About IMXI International Money Express Inc.

International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: